Seeman P.
Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al.
J Clin Psychopharmacol
.
2012 Apr
;
32(2):291-2; author reply 292-293.
PubMed
Abstract